KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...

Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine ...

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).

Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...

Korro’s Chief Medical Officer, Kemi Olugemo, MD, emphasized the importance of developing new treatments for AATD, noting the potential of KRRO-110 to treat liver and lung manifestations of the ...

Todd Chappell, Chief KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to ...

“KRRO-110 has the potential to treat both liver and lung manifestations of AATD, and we are committed to addressing the unmet need and advancing this potentially best-in-class therapy for people ...